Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. (Q46038515)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 April 2009

Language	Label	Description	Also known as
English	Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.	scientific article published on 24 April 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Takao Saruta

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Koichi Hayashi

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Toshio Ogihara

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Kazuwa Nakao

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Tsuguya Fukui

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Kohshiro Fukiyama

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

CASE-J Study Group

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

publication date

24 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Hypertension Research

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

32

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

505-512

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Level of kidney function as a risk factor for cardiovascular outcomes in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Proteinuria and the risk of developing end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

CADASIL: a monogenic condition causing stroke and subcortical vascular dementia

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Chronic kidney disease and mortality risk: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Chronic kidney disease: effects on the cardiovascular system

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Insulin resistance in patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Vascular and metabolic effects of candesartan: insights from therapeutic interventions.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

21 January 2018

Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the management of hypertension for general practitioners

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.44

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/HR.2009.44

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

release_2wbuh47pn5hldphiibtqlzdxae

1 reference

https://api.fatcat.wiki/v0/release/2wbuh47pn5hldphiibtqlzdxae

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19390535

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46038515&oldid=2207557757"